Abstract
G protein-coupled receptors (GPCRs), such as β-adrenergic and angiotensin II receptors, located in the membranes of all three major cardiac cell types, i.e. myocytes, fibroblasts and endothelial cells, play crucial roles in regulating cardiac function and morphology. Their importance in cardiac physiology and disease is reflected by the fact that, collectively, they represent the direct targets of over a third of the currently approved cardiovascular drugs used in clinical practice. Over the past few decades, advances in elucidation of their structure, function and the signaling pathways they elicit, specifically in the heart, have led to identification of an increasing number of new molecular targets for heart disease therapy. Here, we review these signaling modalities employed by GPCRs known to be expressed in the cardiac myocyte membranes and to directly modulate cardiac contractility. We also highlight drugs and drug classes that directly target these GPCRs to modulate cardiac function, as well as molecules involved in cardiac GPCR signaling that have the potential of becoming novel drug targets for modulation of cardiac function in the future.
| Original language | English |
|---|---|
| Pages (from-to) | 143-148 |
| Number of pages | 6 |
| Journal | European Journal of Pharmacology |
| Volume | 763 |
| Issue number | Pt B |
| DOIs | |
| State | Published - Sep 15 2015 |
Bibliographical note
Copyright © 2015 Elsevier B.V. All rights reserved.ASJC Scopus Subject Areas
- Pharmacology
Keywords
- Cardiac
- Contractility
- G protein-coupled receptor
- Signaling
- Therapeutic target
- Myocardial Contraction
- Animals
- Signal Transduction
- Humans
- Receptors, G-Protein-Coupled/metabolism
- Heart/physiology
Disciplines
- Pharmacology, Toxicology and Environmental Health